Topics Covered:
• Pembrolizumab in the adjuvant setting
• Criteria for patient selection post-nephrectomy
• Managing recurrence after pembrolizumab
• IO-IO vs. IO-TKI regimens
• The role of NGS in kidney cancer
• Challenges in treating non-clear cell histologies
Drs. Barragan-Carrillo and Braun, delved into the latest advancements in kidney cancer treatment, focusing on the use of pembrolizumab in the adjuvant setting and the criteria for patient selection post-nephrectomy. Dr. Braun shared his approach to managing patients who experience recurrence after receiving pembrolizumab, discussed the challenges posed by the lack of high-quality data in this area. The conversation also touched on the ongoing debate between IO-IO and IO-TKI regimens, with Dr. Braun explaining the factors that influences his treatment decisions.
Additionally, they explored the role of next-generation sequencing (NGS) in guiding therapy for kidney cancer and the complexities of treating patients with non-clear cell histologies in the metastatic setting.